Ole Schjerning

824 total citations
15 papers, 608 citations indexed

About

Ole Schjerning is a scholar working on Psychiatry and Mental health, Pharmacology and Physiology. According to data from OpenAlex, Ole Schjerning has authored 15 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 5 papers in Pharmacology and 5 papers in Physiology. Recurrent topics in Ole Schjerning's work include Schizophrenia research and treatment (10 papers), Diet and metabolism studies (4 papers) and Diabetes Treatment and Management (3 papers). Ole Schjerning is often cited by papers focused on Schizophrenia research and treatment (10 papers), Diet and metabolism studies (4 papers) and Diabetes Treatment and Management (3 papers). Ole Schjerning collaborates with scholars based in Denmark, United States and Germany. Ole Schjerning's co-authors include Jimmi Nielsen, Per Damkier, Mary Rosenzweig, Anton Pottegård, Anders Fink‐Jensen, Claus Thorn Ekstrøm, Christoph U. Correll, Hans Søe Riis Jespersen, Julie Rask Larsen and David Taylor and has published in prestigious journals such as Schizophrenia Research, Acta Psychiatrica Scandinavica and JAMA Psychiatry.

In The Last Decade

Ole Schjerning

15 papers receiving 585 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ole Schjerning Denmark	9	285	168	145	117	94	15	608
Tara B. Daley United States	9	547 1.9×	240 1.4×	128 0.9×	320 2.7×	40 0.4×	9	759
Madhubhashinee Dayabandara Sri Lanka	7	249 0.9×	119 0.7×	80 0.6×	142 1.2×	33 0.4×	17	465
Chathurie Suraweera Sri Lanka	9	308 1.1×	116 0.7×	83 0.6×	147 1.3×	19 0.2×	26	581
Hiram Joseph Wildgust United Kingdom	13	436 1.5×	90 0.5×	85 0.6×	87 0.7×	31 0.3×	18	734
Candy W. Y. Law Canada	8	282 1.0×	144 0.9×	66 0.5×	162 1.4×	38 0.4×	9	640
I. Kurzthaler Austria	15	462 1.6×	74 0.4×	126 0.9×	76 0.6×	38 0.4×	31	704
Nikhil Nihalani United States	13	174 0.6×	56 0.3×	103 0.7×	114 1.0×	59 0.6×	25	537
Hannah Newall Australia	8	205 0.7×	53 0.3×	68 0.5×	110 0.9×	100 1.1×	8	422
Matthew A. Fuller United States	18	570 2.0×	131 0.8×	167 1.2×	82 0.7×	15 0.2×	52	835
Irene Romera Spain	13	147 0.5×	178 1.1×	224 1.5×	29 0.2×	38 0.4×	36	641

Countries citing papers authored by Ole Schjerning

Since Specialization

Citations

This map shows the geographic impact of Ole Schjerning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ole Schjerning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ole Schjerning more than expected).

Fields of papers citing papers by Ole Schjerning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ole Schjerning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ole Schjerning. The network helps show where Ole Schjerning may publish in the future.

Co-authorship network of co-authors of Ole Schjerning

This figure shows the co-authorship network connecting the top 25 collaborators of Ole Schjerning. A scholar is included among the top collaborators of Ole Schjerning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ole Schjerning. Ole Schjerning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Bricca, Alessio, et al.. (2025). Ethnic disparities in rapid tranquillisation use and justifications in adult mental health inpatient settings: a systematic review and meta-analysis. BMJ Mental Health. 28(1). e301399–e301399. 1 indexed citations

Tomasik, Jakub, Nitin Rustogi, Julie Rask Larsen, et al.. (2020). Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. Schizophrenia Bulletin Open. 1(1). 3 indexed citations

Graff, Claus, et al.. (2019). Mortality rate trends in patients diagnosed with schizophrenia or bipolar disorder: a nationwide study with 20 years of follow-up. International Journal of Bipolar Disorders. 7(1). 6–6. 68 indexed citations

Larsen, Julie Rask, Camilla Kara Svensson, Louise Vedtofte, et al.. (2018). High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectrums. 24(4). 441–452. 23 indexed citations

Svensson, Camilla Kara, Julie Rask Larsen, Louise Vedtofte, et al.. (2018). One‐year follow‐up on liraglutide treatment for prediabetes and overweight/obesity in clozapine‐ or olanzapine‐treated patients. Acta Psychiatrica Scandinavica. 139(1). 26–36. 48 indexed citations

Vang, Torkel, et al.. (2017). Antipsychotic-associated psoriatic rash – a case report. BMC Psychiatry. 17(1). 242–242. 7 indexed citations

Schjerning, Ole, et al.. (2017). Pregabalin for anxiety in patients with schizophrenia — A randomized, double-blind placebo-controlled study. Schizophrenia Research. 195. 260–266. 8 indexed citations

Jakobsen, Klaus D., et al.. (2017). Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. Journal of Psychopharmacology. 31(4). 397–405. 11 indexed citations

Larsen, Julie Rask, Louise Vedtofte, Hans Søe Riis Jespersen, et al.. (2017). Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. JAMA Psychiatry. 74(7). 719–719. 153 indexed citations

10.

Schjerning, Ole, Mary Rosenzweig, Anton Pottegård, Per Damkier, & Jimmi Nielsen. (2016). Abuse Potential of Pregabalin. CNS Drugs. 30(1). 9–25. 114 indexed citations

11.

Polcwiartek, Christoffer, Kristian Kragholm, Ole Schjerning, Claus Graff, & Jimmi Nielsen. (2016). Cardiovascular safety of antipsychotics: a clinical overview. Expert Opinion on Drug Safety. 15(5). 679–688. 43 indexed citations

12.

Schjerning, Ole, Anton Pottegård, Per Damkier, Mary Rosenzweig, & Jimmi Nielsen. (2016). Use of Pregabalin – A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential. Pharmacopsychiatry. 49(4). 155–161. 46 indexed citations

13.

Schjerning, Ole, et al.. (2014). Possible Drug-drug Interaction between Pregabalin and Clozapine in Patients with Schizophrenia: Clinical Perspectives. Pharmacopsychiatry. 48(1). 15–18. 5 indexed citations

14.

Nielsen, Jimmi, Rasmus Røge, Ole Schjerning, Holger J. Sørensen, & David Taylor. (2012). Geographical and temporal variations in clozapine prescription for schizophrenia. European Neuropsychopharmacology. 22(11). 818–824. 75 indexed citations

15.

Schjerning, Ole, Torben Bjerregaard Larsen, & Per Damkier. (2009). The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. Thrombosis Research. 124(2). 208–212. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact